{
  "id": "inactivated-vaccine",
  "title": "Inactivated vaccine",
  "lang": "en",
  "source_lang": "en",
  "summary": "An inactivated vaccine uses pathogens rendered noninfectious to stimulate protective immunity without allowing the vaccine organism to replicate.",
  "category": "health",
  "subcategory": "drugs",
  "type": "concept",
  "aliases": [
    "Killed vaccine",
    "Whole-inactivated vaccine"
  ],
  "generated_at": "2026-11-03",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/inactivated-vaccine/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/inactivated-vaccine/",
      "json": "https://aiwiki.page/zh/inactivated-vaccine.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "An inactivated vaccine is a vaccine made from viruses or bacteria that have been rendered noninfectious while retaining components recognizable by the immune system. These preparations stimulate immunity without replication of the vaccine organism in the recipient. In the strict sense, the term refers to whole-organism vaccines; some broader classifications also group other non-live vaccines under the heading “inactivated.”"
    },
    {
      "heading": "Definition and classification",
      "text": "Inactivation differs from attenuation. A live attenuated vaccine contains a living organism with reduced disease-causing ability that can still replicate under suitable conditions. An inactivated vaccine contains organisms whose infectivity has been eliminated through a validated manufacturing process.\n\n“Inactivated” and “non-live” are therefore not always interchangeable:\n\n- Whole-inactivated vaccines contain killed bacteria or inactivated virus particles.\n- Split-virus vaccines contain disrupted viral particles rather than intact organisms.\n- Subunit vaccines contain selected components of a pathogen.\n- Toxoid vaccines contain inactivated bacterial toxins rather than whole bacteria.\n- Conjugate vaccines link an antigen, commonly a bacterial polysaccharide, to a carrier protein.\n\nThese distinctions describe how a vaccine is made and what it contains, not a universal ranking of safety or effectiveness. A single disease may be preventable by vaccines using several different technologies."
    },
    {
      "heading": "Production and quality control",
      "text": "Production typically begins by growing the target organism in a suitable culture system, such as bacterial growth media, cell cultures, or embryonated eggs. The harvested material undergoes purification and inactivation, with the exact sequence depending on the product.\n\nCommon inactivating agents include formaldehyde and beta-propiolactone. Some manufacturing processes use heat or other physical methods. The central technical challenge is to eliminate infectivity while preserving the molecular structures needed to induce protective immunity. Excessive treatment may damage these structures, whereas insufficient treatment may leave infectious material.\n\nManufacturing controls therefore address several separate requirements:\n\n- Consistent identity and growth of the vaccine organism.\n- Validated inactivation conditions, including treatment time, temperature, and chemical concentration.\n- Testing for residual infectivity and unwanted contaminants.\n- Measurement of antigen content and biological potency.\n- Control of residual processing chemicals and other manufacturing materials.\n\nSome formulations include a vaccine adjuvant, such as an aluminium salt, to enhance the immune response. Adjuvants are not present in every inactivated vaccine."
    },
    {
      "heading": "Immune response",
      "text": "After administration, immune cells take up vaccine material and recognize its antigens. Antigen presentation can activate helper T cells, which support the production of antibodies and the development of immune memory. Protective antibodies may block viral entry into cells, interfere with bacterial attachment, or promote pathogen clearance.\n\nBecause the vaccine organism does not replicate, the amount of antigen does not increase through infection within the recipient. Many inactivated vaccines consequently use a series of initial doses, and some require later booster doses. The number and timing of doses are specific to each product and population.\n\nTheir immune responses are often predominantly antibody-mediated. They generally induce less direct cytotoxic T-cell stimulation than replicating vaccines, although cellular responses vary with the antigen, formulation, adjuvant, and administration route.\n\nSystemic protection and protection at mucosal surfaces are also distinct. An injected inactivated vaccine may prevent severe disease effectively while producing less immunity at the site where a pathogen enters the body. Inactivated poliovirus vaccine, for example, provides strong protection against paralytic disease but generally induces less intestinal immunity than live oral poliovirus vaccine. This difference matters when evaluating effects on infection and transmission."
    },
    {
      "heading": "Examples and uses",
      "text": "Established examples include vaccines against:\n\nDisease | Inactivated vaccine characteristics\nPoliomyelitis | Inactivated poliovirus vaccine contains noninfectious poliovirus and is administered by injection.\nHepatitis A | Widely used injectable formulations contain inactivated hepatitis A virus.\nRabies | Modern human vaccines include inactivated rabies virus grown in cell culture or other approved production systems.\n[[influenza | Influenza]]\nJapanese encephalitis | Inactivated products exist alongside vaccines using other platforms.\n[[cholera | Cholera]]\n[[covid-19 | COVID-19]]\n\nWhole-cell pertussis vaccine is another bacterial example. It contains killed Bordetella pertussis and differs from acellular pertussis vaccines, which contain selected bacterial antigens.\n\nMost familiar inactivated viral vaccines are injected, but inactivation does not determine the route of administration. Killed oral cholera vaccines demonstrate that non-live whole-organism vaccines can also be administered through the digestive tract."
    },
    {
      "heading": "Safety and limitations",
      "text": "A correctly manufactured inactivated vaccine cannot cause infection through replication of its vaccine organism and cannot revert to a more virulent replicating form. This distinguishes it from live vaccines, particularly in the context of immunodeficiency or immunosuppression. Nevertheless, an impaired immune system may produce a weaker response to a non-live vaccine.\n\nNoninfectiousness does not mean an absence of adverse effects. Injection-site pain, redness, swelling, and transient fever can occur, with their frequency depending on the product. Severe allergic reactions, including anaphylaxis, are rare but recognized risks of vaccination. Safety assessment concerns the complete formulation and manufacturing process, not inactivation alone.\n\nOther limitations include the possible need for repeated doses, waning immunity, antigenic changes in circulating pathogens, and manufacturing facilities capable of safely handling infectious organisms before inactivation. Storage requirements remain product-specific: many liquid, aluminium-adjuvanted vaccines are damaged by freezing, and inactivated status does not remove the need for controlled storage.\n\nEffectiveness is established through clinical trials and population studies, rather than inferred solely from antibody production. Outcomes may include prevention of infection, symptomatic illness, hospitalization, or death; protection against one outcome does not necessarily imply equivalent protection against the others. Post-authorization pharmacovigilance continues to assess safety during wider use."
    },
    {
      "heading": "Historical development",
      "text": "Killed bacterial vaccines were developed in the late nineteenth and early twentieth centuries. A major milestone was the introduction of Jonas Salk’s inactivated poliovirus vaccine in 1955, which became an important tool in preventing paralytic poliomyelitis.\n\nThe 1955 Cutter incident, in which some vaccine lots contained incompletely inactivated poliovirus and caused cases of polio, demonstrated the consequences of manufacturing failure. It contributed to tighter production controls and regulatory oversight. The incident concerned residual infectious virus, not reversion of an organism that had been successfully inactivated."
    }
  ],
  "links": [
    "vaccine",
    "bacteria",
    "immune-system",
    "live-attenuated-vaccine",
    "subunit-vaccine",
    "toxoid-vaccine",
    "conjugate-vaccine",
    "vaccine-adjuvant",
    "t-cell",
    "antibody",
    "influenza",
    "cholera",
    "covid-19",
    "immunodeficiency",
    "immunosuppression",
    "fever",
    "anaphylaxis",
    "clinical-trial",
    "pharmacovigilance"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}